Pharmacokinetic Properties of Lorcaserin in Subjects With Hepatic Impairment

Eisai

Status and phase: Completed; Phase 1

Conditions: Hepatic Impairment

Treatments: Drug: Lorcaserin

Study type: Interventional

Funder types: Industry

Identifiers

NCT00828932

APD356-017

Details and patient eligibility

About

The purpose of this study is to evaluate and establish whether lorcaserin dose adjustment is required in patients with mild or moderate hepatic impairment.

Enrollment: 24 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Males or females aged between 18 and 75 years (inclusive)

2. Able to give signed informed consent

3. Hepatic function will fall into one of the following categories:

   • One-third of patients will have normal hepatic function (defined as having all of the following parameters within the normal range of the clinical laboratory used for this trial: AST, ALT, alkaline phosphatase, total bilirubin)
   • One-third of patients will have mild impairment (Child-Pugh score 5-6)
   • One-third of patients will have moderate impairment (Child-Pugh score 7-9)

4. All subjects will have a BMI of 27-45 kg/m2, inclusive.

5. Eligible male and female patients must agree not to participate in a conception process

6. Considered to be in stable health in the opinion of the Investigator.

Exclusion criteria

1. Prior participation in any study of lorcaserin.

2. Clinically significant new illness in the 1 month before screening

3. Not suitable to participate in the study in the opinion of the Investigator including an existing physical or mental condition that prevents compliance with the protocol

4. History of any of the following cardiovascular conditions:

   • Myocardial infarction (diagnosed by cardiac enzyme[s] and/or diagnostic ECG), CVA, TIA or RIND within 6 months of screening
   • Cardiac arrhythmia requiring initiation of new medical or surgical treatment within 6 months of screening (stable medical therapy for > 6 months, pacemakers and/or defibrillators implanted > 6 months prior to screening are acceptable)
   • Unstable angina

5. Surgically implanted portacaval shunts are excluded with the following exception: transjugular intrahepatic portosystemic shunts (TIPS) will be allowed if placed no less than 3 months prior to dosing

6. Malignancy within 2 years of the screening visit (except basal cell or squamous cell carcinoma with clean surgical margins)

7. Initiation of a new prescription medication within 1 month prior to screening.

8. Recent history (within 3 months prior to the screening visit) of alcohol or drug/solvent abuse or a positive screen for drugs of abuse at screening.

9. Use of SSRI's, SNRI's, and other medications must meet the required washout periods.

10. Participated in any clinical study with an investigational drug, biologic, or device within 1 month prior to dosing

Trial design

Primary purpose: Other

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

24 participants in 1 patient group

Lorcaserin 10mg

Experimental group

Treatment:

Drug: Lorcaserin